好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Thrombolysis in Stroke Caused by Infective Endocarditis May Not Be Effective
Cerebrovascular Disease and Interventional Neurology
S49 - (-)
005
Cerebral ischemic events are highly prevalent and associated with high rates of death and disability in patients with IE.
We analyzed the data obtained as part of the Nationwide Inpatient Sample. All patients admitted to hospitals between 2002 and 2010 with primary discharge diagnosis of stroke (identified by the International Classification of Disease, Ninth Revision) and secondary diagnosis of IE were included. Patients with AIS secondary to IE treated with IV thrombolysis were compared to those treated for AIS secondary to other etiologies. Outcomes were defined as rates of intracerebral hemorrhage (ICH), in-hospital mortality, or favorable outcome (discharge disposition of home/self-care).
There were 222 patients (mean age 59卤18 years, 46% women) who were treated with IV thrombolysis for AIS secondary to IE as compared to 134,048 patients (mean age 69卤15 years, 49% women) who were treated for AIS secondary to other etiologies. The rate of ICH was significantly greater in the IE group compared to the non-IE AIS treated group (20% vs 6%, p=0.001). There was no difference in rate of in-hospital mortality between the two groups (p=0.5); however, there was a significantly lower rate of favorable outcome in the IE group when compared to the non-IE AIS treated group (10% vs 37%, p=0.01).
The high rate of ICH and low rates of favorable outcome mandate caution in utilizing IV thrombolysis in patients with AIS secondary to IE.
Authors/Disclosures
Ganesh Asaithambi, MD, FAAN (Allina Health Neuroscience Institute)
PRESENTER 		Dr. Asaithambi has nothing to disclose.
No disclosure on file
Jeffrey A. Cohen, MD (Cleveland Clinic) Dr. Cohen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Convelo. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astoria. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atara. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viatris. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celltrion. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sage.
Hamza I. Maqsood, MD (Dept of Neurology) Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.